p53 binding to nucleosomes within the p21 promoter in vivo leads to nucleosome loss and transcriptional activation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 26, 2011, Pages 10385-10390

  Laptenko, Oleg ^a   Beckerman, Rachel ^a   Freulich, Ella ^a   Prives, Carol ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

DNA binding; DNA damage

Indexed keywords

DOXORUBICIN; NUTLIN 3; PROTEIN P21; PROTEIN P53;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL STRAIN HCT116; CELL STRESS; CELLULAR DISTRIBUTION; COLON CARCINOMA; CONTROLLED STUDY; DNA BINDING; GENE; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; NUCLEOSOME; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; TRANSCRIPTION INITIATION;

CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA; HUMANS; NUCLEOSOMES; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS P21(RAS); TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79960600521     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1105680108     Document Type: Article

References (31)

1. Kornberg RD (1974) Chromatin structure: A repeating unit of histones and DNA. Science 184:868-871.
2. Kornberg RD, Tomas JO (1974) Chromatin structure: Oligomers of the histones. Science 184:865-868.
3. Luger K, et al. (1997) Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389:251-260. (Pubitemid 27406632)
4. Peterson CL, Workman JL (2000) Promoter targeting and chromatin remodeling by SWI/SNF complex. Curr Opin Genet Dev 10:187-192. (Pubitemid 30182252)
5. Li B, Adams CC, Workman JL (1994) Nucleosome binding by the constitutive transcription factor Sp1. J Biol Chem 269:7756-7763. (Pubitemid 24217991)
6. Shilatifard A (2008) Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr Opin Cell Biol 20:341-348.
7. Cirillo LA, et al. (2002) Opening of chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell 9:279-289. (Pubitemid 34195554)
8. Laptenko O, Prives C (2006) Transcriptional regulation by p53: One protein, many possibilities. Cell Death Differ 13:951-961.
9. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B (1992) Definition of a consensus binding site for p53. Nat Genet 1:45-49.
10. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW (1992) A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12:2866-2871.
11. Riley T, Sontag E, Chen P, Levine A (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9:402-412.
12. el-Deiry WS, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
13. El-Deiry WS, et al. (1995) Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55:2910-2919.
14. Macleod KF, et al. (1995) p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9:935-944.
15. Bunz F, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501. (Pubitemid 28538613)
16. Coisy M, et al. (2004) Cyclin A repression in quiescent cells is associated with chromatin remodeling of its promoter and requires Brahma/SNF2alpha. Mol Cell 15:43-56. (Pubitemid 38850218)
17. Espinosa JM, Verdun RE, Emerson BM (2003) p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol Cell 12:1015-1027. (Pubitemid 37352792)
18. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741.
19. Vassilev LT, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848.
20. Noll M (1974) Internal structure of the chromatin subunit. Nucleic Acids Res 1:1573-1578.
21. Anderson JD, Widom J (2000) Sequence and position-dependence of the equilibrium accessibility of nucleosomal DNA target sites. J Mol Biol 296:979-987.
22. Xiong Y, et al. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704. (Pubitemid 24036020)
23. Dechassa ML, et al. (2010) SWI/SNF has intrinsic nucleosome disassembly activity that is dependent on adjacent nucleosomes. Mol Cell 38:590-602.
24. Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265:346-355. (Pubitemid 24259959)
25. Kitayner M, et al. (2006) Structural basis of DNA recognition by p53 tetramers. Mol Cell 22:741-753.
26. Hager GL, McNally JG, Misteli T (2009) Transcription dynamics. Mol Cell 35:741-753.
27. Segal E, Widom J (2009) What controls nucleosome positions? Trends Genet 25:335-343.
28. Gévry N, et al. (2007) p21 transcription is regulated by differential localization of histone H2A.Z. Genes Dev 21:1869-1881. (Pubitemid 47204927)
29. Guillemette B, Gaudreau L (2006) Reuniting the contrasting functions of H2A.Z. Biochem Cell Biol 84:528-535. (Pubitemid 44703656)
30. Sahu G, et al. (2010) p53 binding to nucleosomal DNA depends on the rotational positioning of DNA response element. J Biol Chem 285:1321-1332.
31. Lidor NE, et al. (2010) p53 binds preferentially to genomic regions with high DNA-encoded nucleosome occupancy. Genome Res 20:1361-1368.